ViroGates A/S

ViroGates A/S Equity

The The Equity of ViroGates A/S (VIRO.CO) as of Oct 18, 2026 is 19.40 M DKK. In the previous year, The Equity was 10.80 M DKK — a change of 79.74% (higher).

Equity

19.40 MDKK

YoY

79.74%

Last updated:

In 2025, ViroGates A/S's equity was 19.40 M DKK, a 79.74% increase from the 10.80 M DKK equity in the previous year.

The ViroGates A/S Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
61.01 M DKK
Jan 1, 2019
42.22 M DKK
Jan 1, 2020
31.31 M DKK
Jan 1, 2021
16.43 M DKK
Jan 1, 2022
16.09 M DKK
Jan 1, 2023
17.01 M DKK
Jan 1, 2024
10.80 M DKK
Jan 1, 2025
19.40 M DKK
The ViroGates A/S Equity history
YEAREquityYoY
19.40 MDKK+79.74%
10.80 MDKK-36.53%
17.01 MDKK+5.71%
16.09 MDKK-2.06%
16.43 MDKK-47.54%
31.31 MDKK-25.82%
42.22 MDKK-30.81%
61.01 MDKK+1,935.74%
3.00 MDKK-66.64%
8.99 MDKK-37.55%
14.39 MDKK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ViroGates A/S Stock analysis

What does ViroGates A/S do? ViroGates A/S, listed on the Copenhagen Stock Exchange with ticker VIRO.CO, operates in the Health Care sector. The company develops and markets diagnostic products, including the suPARnostic line, which measures soluble urokinase Plasminogen Activator Receptor (suPAR) in blood. suPAR levels indicate immune activation and are linked to infectious diseases such as HIV-1, malaria, tuberculosis, and sepsis. suPARnostic offers a Quantitative Point of Care Quick Triage test for acute care triage and a Quantitative ELISA Assay for clinical use. The company has 28 employees and was listed in 2018. ViroGates A/S is one of the most popular companies on Eulerpool.

Equity Details

Analyzing ViroGates A/S's Equity

ViroGates A/S's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ViroGates A/S's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating ViroGates A/S's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

ViroGates A/S's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in ViroGates A/S’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about ViroGates A/S stock

The Equity of ViroGates A/S is 19.40 M DKK in 2025.

The Equity of ViroGates A/S changed from 10.80 M DKK to 19.40 M DKK, representing a 79.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity ViroGates A/S since 2006 – with annual values, charts, and detailed analysis.

The Equity's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's ViroGates A/S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — ViroGates A/S

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — ViroGates A/S